Conference Day Two

September 23, 2025

8:00 am One-on-One PartneringTM portal meeting schedule starts

Synopsis

Grab a coffee and sit down with key contacts in the hour before the conference at bookable meeting spaces

8:30 am Chair’s Opening Remarks

Evaluating B-Cell Depletion & Targeting Insights to Advance Immune Cell Targeting & Combat Complex Autoimmune Diseases

8:40 am Company Presentation Opportunity

9:10 am Unlocking New Immune Pathways: Discussing B-Cell Depletion & Beyond in Autoimmune Therapy

  • Nick Veomett Vice President Corporate Development, Artiva Biotherapeutics, Inc
  • Dan Mazaisz Chief Business Officer, Kyverna Therapeutics, Inc.
  • Dan Passeri President & Chief Executive Officer, Cue Biopharma
  • Daniela Cipolletta Senior Director of Immunology, Seismic Therapeutic

Synopsis

  • Discussing the latest B-cell depletion data across diseases to assess effectiveness and potential for expansion into dermatological diseases such as psoriasis
  • Evaluating if B-cell depletion remains the most promising approach and exploring the potential to move beyond B-cell targeting (including, Mast Cells, T-cells, Macrophages, Myeloid Cells and more)
  • Exploring immune cell depletion across disease indications to expand treatments across complex and diversely derived indications

9:45 am Morning Break & Networking

10:00 am One-one-One Meeting Schedule Available during Extended Break

Synopsis

With Day One an opportunity to establish connections and break the ice, leverage extended breaks during Day Two’s schedule to sit down with slide decks and make a lasting impression. 

12:10 pm Evaluating Bi-Specific Antibody & Cell Engager Targets, Safety & Efficacy to Uncover Their Commercial Potential

Synopsis

  • Exploring emerging classes of cell engager and bispecific therapies, evaluating target populations, including macrophages, to identify applications in wider autoimmune diseases
  • Comparing toxicity concerns for a broad population or efficacy in more targeted populations to evaluate the safety of engager and antibody applications
  • Evaluating the safety and efficacy of bispecific antibody & cell engagers, in comparison to autologous CAR-T therapies to evaluate their potential in the autoimmunity market

12:40 pm Lunch Break & Networking

Utilizing Novel Therapies & Combination Therapies to Enhance Target Diversity & Specificity

2:00 pm Revolutionizing Inflammatory Disease Treatment with Carocell Bio’s Next-Generation Peptide Therapy

  • Mike Davies Founder & Chief Executive Officer, Carocell Bio Ltd.

Synopsis

  • Introducing Carocell Bio, revolutionizing inflammatory therapies with next-generation anti-inflammatory peptides 
  • Uncovering Carocell Bio’s positive JEL3108 therapy preclinical data targeting atopic dermatitiss  
  • Highlighting the diversification of effective treatment options for patients utilizing Carocell Bio’s JEL3108 therapy to delay aging of the skin  

3:00 pm Uncovering Modality, Precision Targeting & Global Partnership Synergies to Advance Autoimmune Combination Therapy Innovations

  • Stuart Chaffee Chief Executive Officer, QuantX Biosciences
  • Avirup Bose Vice President, Corporate Development, InduPro, Inc
  • Zaneta Odrowaz Chief Business Officer, Attovia Therapeutics
  • Carter King Executive Vice President - Business Development, Protagonist Therapeutics, Inc.
  • Daniela Cipolletta Senior Director of Immunology, Seismic Therapeutic

Synopsis

  • Discussing optimal modality combinations, considering checkpoint agonism, bispecific, monoclonal and fixed dose oral approaches, to safety tailor combinations for complex autoimmune diseases, including IBD and RA
  • Evaluating the balance of known and novel targets to align with safety profiles and unmet patient needs
  • Exploring partnership opportunities with the rapidly expanding bispecific market in Asia and the impact of cross boarder collaboration on innovation and access

3:30 pm Chair’s Closing Remarks